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Background-—The incidence and predictors of atrial ﬁbrillation (AF) progression are currently not well deﬁned, and clinical AF
progression partly overlaps with rhythm control interventions (RCIs).
Methods and Results-—We assessed AF type and intercurrent RCIs during yearly follow-ups in 2869 prospectively followed
patients with paroxysmal or persistent AF. Clinical AF progression was deﬁned as progression from paroxysmal to nonparoxysmal
or from persistent to permanent AF. An RCI was deﬁned as pulmonary vein isolation, electrical cardioversion, or new treatment
with amiodarone. During a median follow-up of 3 years, the incidence of clinical AF progression was 5.2 per 100 patient-years, and
10.9 per 100 patient-years for any RCI. Signiﬁcant predictors for AF progression were body mass index (hazard ratio [HR], 1.03;
95% CI, 1.01–1.05), heart rate (HR per 5 beats/min increase, 1.05; 95% CI, 1.02–1.08), age (HR per 5-year increase 1.19; 95% CI,
1.13–1.27), systolic blood pressure (HR per 5 mm Hg increase, 1.03; 95% CI, 1.00–1.05), history of hyperthyroidism (HR, 1.71;
95% CI, 1.16–2.52), stroke (HR, 1.50; 95% CI, 1.19–1.88), and heart failure (HR, 1.69; 95% CI, 1.34–2.13). Regular physical activity
(HR, 0.80; 95% CI, 0.66–0.98) and previous pulmonary vein isolation (HR, 0.69; 95% CI, 0.53–0.90) showed an inverse association.
Signiﬁcant predictive factors for RCIs were physical activity (HR, 1.42; 95% CI, 1.20–1.68), AF-related symptoms (HR, 1.84; 95% CI,
1.47–2.30), age (HR per 5-year increase, 0.88; 95% CI, 0.85–0.92), and paroxysmal AF (HR, 0.61; 95% CI, 0.51–0.73).
Conclusions-—Cardiovascular risk factors and comorbidities were key predictors of clinical AF progression. A healthy lifestyle may
therefore reduce the risk of AF progression. ( J Am Heart Assoc. 2019;8:e012554. DOI: 10.1161/JAHA.119.012554.)
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C urrent thinking indicates that atrial ﬁbrillation (AF)usually progresses from short, rare episodes to longer
and more frequent attacks.1 Patients who develop more
sustained forms of the disease are less amenable to
treatment and are thought to have a worse outcome.2,3 A
recent meta-analysis suggested a higher risk of thromboem-
bolism and death among patients with sustained compared
with intermittent forms of AF.4
In clinical practice, AF is classiﬁed into paroxysmal,
persistent, or permanent AF.1 Even though the classiﬁcation
poorly reﬂects temporal persistence of the arrhythmia,5 it is
commonly used in daily clinical practice. In a recent meta-
analysis, the cumulative incidence of AF progression was 8.1
per 100 patient-years. Main predictors explaining between-
study heterogeneity were age, hypertension, follow-up dura-
tion, and baseline AF type.6
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However, previous studies did not take into account at
least 2 important issues. First, the change in AF type is not
exclusively unidirectional, as AF may also regress to less
sustained forms, and prior studies have not acknowledged
this. Second, AF progression may be masked to some extent
by the use of rhythm control interventions (RCIs). The most
effective RCIs currently available are antiarrhythmic treatment
with amiodarone, direct electrical cardioversion (ECV) and
pulmonary vein isolation (PVI).7 While RCIs partly overlap with
the deﬁnition of the clinical AF type, they constitute an
independent entity that needs to be taken into account
separately.
A better understanding of clinical AF progression and its
associated risk factors will improve risk prediction and help to
plan speciﬁc intervention studies to prevent AF progression.
In the current study, we aimed to assess the incidence and
associated predictors of clinical AF progression and RCIs in a
large cohort of prospectively followed patients with paroxys-
mal and persistent AF.
Methods
The consent forms, as approved by the local ethics committee
(Ethikkommission Nordwest- und Zentralschweiz), do not
allow the data to be made publicly available. Researchers may
contact the authors for the potential submission of research
proposals for future analyses.
Study Design and Participants
To increase sample size and power, we combined data from 2
ongoing prospective, observational, multicenter cohort studies
of AF patients in Switzerland. Both cohorts used similar
enrollment criteria, outcome deﬁnitions and case report forms.
Between 2010 and 2014, the BEAT-AF (Basel Atrial
Fibrillation) cohort study recruited 1553 patients with docu-
mented AF across 7 centers in Switzerland. The Swiss-AF
(Swiss Atrial Fibrillation) study enrolled 2415 AF patients
between 2014 and 2017 across 14 centers in Switzerland.
The detailed methodology for Swiss-AF was described
earlier.8 In both cohorts, all patients were required to have
previously documented AF. The main exclusion criteria for
both cohorts were the inability to sign informed consent and
secondary forms of AF (eg, AF after cardiac surgery). Patients
with an acute illness within the past 4 weeks could only be
enrolled once the acute episode had resolved. Patients
enrolled in BEAT-AF were not eligible for participation in
Swiss-AF and vice versa.
From the combined data set of BEAT-AF and Swiss-AF, we
excluded 942 (23.7%) patients with permanent AF at baseline.
From the remaining 3026 patients, we excluded 144 (4.8%)
patients without follow-up information on AF type, 8 (0.3%)
patients without follow-up information on RCIs, and 5 (0.1%)
patients with double inclusion, such that 2869 patients
remained in the ﬁnal analyses. For the present analysis, we
used available data up to October 12, 2018.
The study protocols of both studies were approved by the
local ethics committees, and informed written consent was
obtained from each participant.
Assessments
In both cohorts, patients completed similar questionnaires
about personal, medical, nutritional, and lifestyle factors on a
yearly basis. Smoking status was categorized into current
smokers and noncurrent smokers (past or never smokers).
Body mass index (BMI) was calculated as weight in kilograms
divided by height in meters squared. Local investigators
classiﬁed the current AF type according to the 2010 guidelines
of the European Society of Cardiology into paroxysmal AF (self-
terminating, usually within 48 hours), persistent AF (episodes
lasting >7 days or requiring termination by electrical or
medical cardioversion) or permanent AF (AF is accepted by
the patient and the physician, and no further attempts to
restore sinus rhythm are performed).1 For consistency reasons
we did not apply the updated 2016 guidelines in which AF
episodes cardioverted within 7 days are considered paroxys-
mal AF.7 The current AF type was determined by the local study
investigator during the baseline or follow-up visits on the basis
of all available clinical patient data. We did not distinguish
between long-standing persistent and permanent AF. Coronary
artery disease was deﬁned as either a history of myocardial
infarction and/or percutaneous transluminal coronary angio-
plasty and/or coronary bypass graft. Physical activity was
Clinical Perspective
What Is New?
• The incidence for clinical atrial ﬁbrillation (AF) progression
was relatively low (5.2 cases per 100 patient-years of
follow-up).
• Several potentially modiﬁable risk factors and comorbidities
were key predictors of clinical AF progression.
• Patients with and without rhythm control interventions had
a similar AF progression rate, although pulmonary vein
isolation was associated with a lower AF progression rate.
What Are the Clinical Implications?
• A healthy lifestyle may help to reduce the risk of AF
progression.
• The role of rhythm control interventions in the prevention of
AF progression is less clear.
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assessed using a question about whether participants perform
physical activity on a regular basis or not.
After a face-to-face examination at baseline, all yearly
follow-up examinations in BEAT-AF were performed by paper-
based mailed questionnaires and subsequent telephone
interviews. In Swiss-AF, all patients were assessed yearly by
clinical follow-up visits. In both cohorts, patients completed
information about personal factors, and trained study per-
sonnel subsequently updated AF type, comorbidities, medi-
cation, medical interventions, and intercurrent adverse events
during the clinical visits (Swiss-AF) or telephone interviews
(BEAT-AF), respectively. The current AF type was assessed in
both cohorts during each baseline and follow-up visit, into
paroxysmal, persistent, or permanent on the basis of clinical
information and medical reports.
Deﬁnitions and Outcomes
Clinical AF progression was deﬁned as AF progression from
paroxysmal AF at baseline to nonparoxysmal AF (persistent
or permanent AF) at the latest follow-up or as AF
progression from persistent AF at baseline to permanent
AF at the latest follow-up. To take into account AF
regression, intermittent classiﬁcation into higher clinical AF
categories with subsequent regression to the same or a
lower clinical category by the latest follow-up was not
counted as AF progression.
Intercurrent RCI was deﬁned as undergoing either ECV,
PVI, or treatment with amiodarone during prospective follow-
up. For the RCI analyses we excluded all patients (n=597;
20.8%) who were receiving amiodarone at baseline.
Statistical Analysis
Baseline characteristics were stratiﬁed by baseline AF type
(paroxysmal versus persistent). Categorical variables were
presented as numbers (percentages) and compared using v2
tests. The distribution of continuous variables was checked
using kurtosis, skewness, and visual inspection of the
histogram (not presented). They were presented as means
SDs or median (interquartile range) and compared using
Student t tests or Wilcoxon rank-sum tests, as appropriate.
We constructed Kaplan–Meier Cumulative Incidence
Curves for clinical AF progression and RCIs. Differences in
incidence rates for AF progression from paroxysmal AF to
nonparoxysmal AF versus AF progression from persistent AF
to permanent AF were compared using a log-rank test.
To identify independent predictors of clinical AF progres-
sion or RCI, we constructed Cox regression models to
calculate hazard ratios (HRs) and 95% CIs. The proportional
Table 1. Baseline Characteristics Stratiﬁed by Baseline AF Type
Characteristic Paroxysmal (n=1854) Persistent (n=1015) P Value
Age, y 7011 709 0.211
Female sex, N (%) 598 (32.3) 254 (25.0) <0.001
White race, N (%) 1825 (98.4) 1008 (99.3) 0.156
Body mass index, kg/m2 27.04.8 27.84.7 <0.001
Heart rate, beats/min 63 (56–72) 68 (59–80 <0.001
Systolic blood pressure, mm Hg 13519 13419 0.025
History of coronary heart disease, N (%) 430 (23.2) 251 (24.7) 0.355
History of stroke/TIA, N (%) 327 (17.6) 144 (14.2) 0.018
History of hypertension, N (%) 1182 (63.8) 709 (69.9) 0.001
History of heart failure, N (%) 285 (15.4) 278 (27.4) <0.001
History of diabetes mellitus, N (%) 233 (12.6) 148 (14.6) 0.129
History of renal failure, N (%) 263 (14.2) 181 (17.8) 0.010
History of hyperthyroidism, N (%) 55 (3.0) 57 (5.6) <0.001
Current smoker, N (%) 152 (8.2) 86 (8.5) 0.809
Regular physical activity, N (%) 995 (53.9) 490 (48.4) 0.005
History of pulmonary vein isolation, N (%) 476 (25.7) 269 (26.5) 0.640
History of electrical cardioversion, N (%) 336 (18.2) 676 (66.7) <0.001
AF-related symptoms, N (%) 1371 (75.4) 664 (66.1) <0.001
P values are based on v2 tests, Student t tests or Wilcoxon rank-sum tests as appropriate. AF indicates atrial ﬁbrillation; TIA, transient ischemic attack.
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hazard assumption for the Cox models has been assessed by
creating interactions of the predictors and a function of the
survival time (not presented). All models included a predeﬁned
set of covariates: age, sex, BMI, heart rate, systolic blood
pressure, history of diabetes mellitus, history of coronary
artery disease, history of hypertension, history of heart failure,
history of stroke and/or transient ischemic attack, history of
hyperthyroidism, history of renal failure, regular physical
activity, smoking (current versus history/never smoker), AF
type at baseline (paroxysmal versus persistent), history of PVI,
and presence of AF-related symptoms. Regression models on
clinical AF progression were additionally adjusted for amio-
darone treatment at baseline. P values for interaction were
calculated by adding a multiplicative interaction term.
We also performed sensitivity analyses for RCI and clinical
AF progression among patients without a history of PVI or
ECV at baseline.
Statistical analyses were performed using SAS 9.4 (SAS
Corporation, Cary, NC) or STATA software version 12.0
(StataCorp, College Station, TX). A 2-sided P<0.05 was
considered to indicate statistical signiﬁcance.
Results
We included 1854 (65%) patients with paroxysmal and 1015
(35%) patients with persistent AF in the analysis. Baseline
characteristics stratiﬁed by baseline AF type are shown in
Table 1. Age was similar in patients with paroxysmal and
persistent AF (7011 versus 709 years; P=0.211). Patients
with paroxysmal AF had a lower BMI (27.04.8 versus
27.84.7; P<0.001), engaged more often in regular physical
activity (995 [54%] versus 490 [48%]; P=0.005) and reported
more AF-related symptoms (1371 [75%] versus 664 [66%];
P<0.001), while they had a lower prevalence of heart failure
(285 [15%] versus 278 [27%]; P<0.001) and hypertension
(1182 [64%] versus 709 [70%]; P=0.001) (Table 1).
Clinical Atrial Fibrillation Progression
During a median (interquartile range) follow-up of 3.0 (2.0;
5.0) years, 458 of 2869 (16.0%) patients had clinical AF
progression (incidence 5.2 per 100 patient-years of follow-up
(Table S1). The corresponding Kaplan–Meier estimates are
presented in Figure 1. The incidence per 100 patient-years
was 4.9 for AF progression from paroxysmal to nonparoxys-
mal versus 5.8 for AF progression from persistent to
permanent AF (P for difference=0.082; Table S1). When
excluding patients with a history of ECV or PVI at baseline and
those with any RCI during follow-up, 151 of the remaining 963
patients (15.7%) had clinical AF progression, corresponding to
an incidence of 5.4 per 100 patient-years (Table S1).
Predictors for clinical AF progression are presented in
Table 2. BMI (HR, 1.03; 95% CI, 1.01-1.05; P=0.016), heart
rate (HR per 5 beats/min increase, 1.05; 95% CI, 1.02–1.08;
P<0.001), age (HR per 5-year increase, 1.19; 95% CI, 1.13–
Figure 1. Kaplan–Meier estimates for clinical atrial ﬁbrillation progression. The x axis
represents the time of follow-up in years. The y axis represents freedom from clinical atrial
ﬁbrillation progression.
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1.27; P<0.001), systolic blood pressure (HR per 5 mm Hg,
1.03; 95% CI, 1.00–1.05; P=0.050), history of hyperthyroidism
(HR, 1.71; 95% CI, 1.16–2.52; P=0.007), history of stroke/
transient ischemic attack (HR, 1.50; 95% CI, 1.20; 1.88;
P<0.001) and history of heart failure (HR, 1.69; 95% CI, 1.34–
2.13; P<0.001) were associated with a higher incidence of AF
progression. Regular physical activity (HR, 0.80; 95% CI, 0.66–
0.98; P=0.028) and previous PVI (HR, 0.69; 95% CI, 0.53–
0.90; P=0.006) were protective for AF progression. The
associations were widely comparable, both in direction and
magnitude, in models that were stratiﬁed for either baseline
AF type or study cohort (Tables S2 and S3).
Rhythm Control Interventions
During follow-up, 617 of 2272 patients (27.2%) not on
amiodarone treatment at baseline were treated with an RCI,
deﬁned as either a PVI and/or ECV and/or new treatment
with amiodarone (incidence, 10.9 per 100 patient-years of
follow-up; Figure 2 and Table S1). When separating the
combined RCI end point into its components, there were 199
(8.8%) patients receiving newly prescribed amiodarone (inci-
dence, 2.8 per 100 patient-years), 282 (12.4%) having ≥1
ECVs (incidence, 4.2 per 100 patient-years), and 358 (15.8%)
having ≥1 PVI (incidence, 5.7 per 100 patient-years;
Table S1). Among 1221 patients without a history of PVI or
ECV at baseline, 258 (21.1%) had any RCI during follow-up.
The corresponding incidence was 8.0 per 100 patient-years of
follow-up (Table S1). Patients who were receiving a PVI during
follow-up were younger (6210 versus 6810 versus 736;
P<0.001), had a lower BMI (264 versus 284 versus 285;
P<0.001) and reported more often to perform regular physical
activity (144 [67%] versus 64 [60%] versus 56 [57%]; P<0.001)
than patients treated with ECV or amiodarone. On the other
hand, most of the comorbidities were more prevalent among
patients receiving an ECV or amiodarone during follow-up
compared with those treated with a PVI (Table S4).
Table 3 shows the association of covariates with any RCI
during follow-up. Variables independently associated with RCI
were regular physical activity (HR, 1.42; 95% CI, 1.20–1.68;
P<0.001), AF-related symptoms at baseline (HR, 1.84; 95% CI,
1.47–2.30; P<0.001), age (HR per 5-year increase, 0.88; 95%
CI, 0.85–0.92; P<0.001), and paroxysmal AF at baseline (HR,
0.61; 95% CI, 0.51–0.73; P<0.001). Exclusion of patients with
a history of PVI and/or ECV at baseline did not inﬂuence the
results (Table S5).
Table 2. Risk Factors for Clinical AF Progression
Characteristic (n=2869) Age/Sex Adjusted P Value Multivariable Adjusted P Value
Age 1.25 (1.19–1.32) <0.001 1.19 (1.13–1.27) <0.001
Female sex 0.85 (0.70–1.04) 0.119 0.87 (0.70–1.08) 0.220
BMI 1.04 (1.02–1.06) <0.001 1.03 (1.01–1.05) 0.016
Heart rate 1.06 (1.03–1.08) <0.001 1.05 (1.02–1.08) <0.001
Systolic blood pressure 1.01 (0.99–1.04) 0.436 1.03 (1.00–1.05) 0.050
History of diabetes mellitus 1.14 (0.88–1.48) 0.328 0.92 (0.69–1.21) 0.549
History of coronary artery disease 1.14 (0.91–1.41) 0.250 0.98 (0.77–1.23) 0.833
History of hypertension 1.14 (0.93–1.41) 0.207 0.94 (0.75–1.18) 0.611
History of stroke and/or TIA 1.51 (1.21–1.88) <0.001 1.50 (1.19–1.88) <0.001
History of heart failure 1.82 (1.48–2.24) <0.001 1.69 (1.34–2.13) <0.001
History of hyperthyroidism 1.72 (1.17–2.51) 0.006 1.71 (1.16–2.52) 0.007
History of renal failure 1.31 (1.03–1.66) 0.029 1.09 (0.84–1.42) 0.514
Regular physical activity 0.72 (0.60–0.87) <0.001 0.80 (0.66–0.98) 0.028
Current smoking 1.19 (0.84–1.68) 0.339 1.04 (0.72–1.49) 0.844
Paroxysmal AF 0.84 (0.69–1.02) 0.072 0.99 (0.80–1.21) 0.903
History of pulmonary vein isolation 0.62 (0.48–0.80) <0.001 0.69 (0.53–0.90) 0.006
AF-related symptoms at baseline 0.82 (0.66–1.01) 0.058 0.86 (0.69–1.06) 0.164
Amiodarone use at baseline 0.97 (0.77–1.22) 0.787 0.89 (0.70–1.13) 0.343
Data are hazard ratios (95% CI) based on Cox regression models. Age per 5-year increase; heart rate per 5 beats/min increase, systolic blood pressure per 5 mm Hg increase;
multivariable models included all variables from the table (age, sex, BMI, heart rate, systolic blood pressure, history of diabetes mellitus, history of coronary artery disease, history of
hypertension, history of stroke/TIA, history of heart failure, history of hyperthyroidism, history of renal failure, regular physical activity, current smoking, history of pulmonary vein isolation,
AF-related symptoms, amiodarone). A maximum of 85 (3.0%) observations were deleted because of missing variables. AF indicates atrial ﬁbrillation; BMI, body mass index; TIA, transient
ischemic attack.
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Discussion
In this large prospective cohort of patients with paroxysmal or
persistent AF, we found that the incidence of clinical AF
progression was relatively low and independent of baseline AF
type. Several risk factors and comorbidities potentially
amenable to therapeutic or lifestyle interventions were
signiﬁcantly associated with AF progression. The incidence
of RCI was twice as high as the incidence of clinical AF
progression, and main determinants for RCI were symptoms,
younger age, and physical activity. RCI did not seem to have a
major impact on the clinical progression rate.
The incidence of clinical AF progression was 5.2 progres-
sion cases per 100 patient-years of follow-up. In a recent
meta-analysis we found a cumulative incidence of clinical AF
progression of 8.1 per 100 patient-years of follow-up.6 Our
slightly revised deﬁnition of AF progression might partly
explain the lower incidence in the current study. The relatively
low incidence of clinical AF progression seems to be in
contrast with the high overall prevalence of nonparoxysmal
AF. For example, in the GARFIELD (Global Anticoagulant
Registry in the FIELD) registry, which enrolled >17 000
patients with newly diagnosed AF almost 30% of the study
participants had nonparoxysmal AF at baseline.9 We observed
a comparable prevalence of 38% nonparoxysmal AF among
patients with recent-onset AF.10 This raises the question of
whether there is a speciﬁc population of AF patients in which
persistent or permanent AF might be the ﬁrst clinical
manifestation of the arrhythmia.
Interestingly, patients without a history of RCI at baseline
and not receiving any RCI during follow-up had a similar
incidence of AF progression as the overall cohort. While a
history of ECV has been incorporated in the deﬁnition of AF
type, the other 2 interventions are independent of it. In our
study, PVI was associated with a lower AF progression rate.
These data are in line with previous studies showing that PVI
is more effective than antiarrhythmic medication in restor-
ing and maintaining sinus rhythm in symptomatic AF
patients.11–13 Moreover, a meta-analysis assessing the rate
of AF progression showed a signiﬁcantly lower AF progression
rate among patients with catheter ablation compared with
patients without an intervention.14 Underlying mechanisms
might include an inverse remodeling of the left atrium after
PVI,15–17 even though the positive effect is still debated.18,19
While these data suggest that PVI may slow the natural
history of AF progression, causality cannot be proven in
observational studies, residual confounding might persist
even after comprehensive multivariable adjustment, and
patient selection may play an important role in this associ-
ation. Our multivariable models suggest that younger and
active individuals with fewer comorbidities are more likely to
receive an RCI, probably reﬂecting this selection process.
Overall, the impact of RCI on the incidence of AF progression
is unclear and needs to be assessed in future studies.
Several factors reﬂecting a healthy lifestyle were inversely
and independently associated with clinical AF progression,
including regular physical activity, a lower BMI, and a lower
systolic blood pressure. Although the relationship between
Figure 2. Kaplan–Meier estimates for rhythm control intervention. The x axis represents the
time of follow-up in years. The y axis represents freedom from rhythm control intervention.
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physical activity and new-onset AF is not clear and may not
be linear,20–22 our study suggests that regular physical
activity might prevent AF progression. Overweight and
obesity have been described as risk factors for new-onset
AF in different cohorts,23–25 possibly mediated by left atrial
dilation.26 BMI was also associated with AF progression from
paroxysmal to permanent, and the hazard ratio was similar
to the one we observed in our study.27 Blood pressure is
closely related to physical activity and BMI. Hypertension
explained 18% of the heterogeneity in a recently published
meta-analysis on risk factors for AF progression.6 The
association of hypertension with new-onset AF was
described earlier, and hypertension is thought to account
for 22% of incident AF cases.28,29 These data show the
importance of blood pressure control for both new-onset AF
and AF progression, and also suggest that a healthy lifestyle
not only plays a key role for primary AF prevention but may
also lower the risk of AF progression.
We are in line with previous studies that history of heart
failure,30–32 history of stroke,2 and increasing age2,31–37 are
associated with clinical AF progression. It is well known that
heart failure is an important comorbidity associated with AF,
and both entities frequently coexist.38 Moreover, older age is
strongly and independently associated with AF.39,40 There
seems to be an overlap of risk factors for AF progression with
predisposing factors for new-onset AF. The factors might lead
to structural and electrical changes in the atria that may
explain the increased risk for AF progression. Possible
changes could include atrial dilation, stiffness of the left
atrium, and increased myocardial ﬁbrosis, but also electro-
anatomical changes and conduction disturbances.41–44 An
additional independent predictor in our analysis was a history
of hyperthyroidism. Subclinical and clinical hyperthyroidism
have been associated with incident AF.45,46 The underlying
causes are currently not completely understood. Possible
mechanisms that may explain the risk for incident AF and AF
progression include elevated left atrial pressure secondary to
impaired left ventricular relaxation,47 ectopic atrial activity,47
and shortening of action potential duration.48 Another patho-
physiological concept suggests an autoimmune-endocrine
disorder. In animal studies, activating autoantibodies to the
b1-adrenergic and M2 muscarinic receptors has shown to
induce AF.49
Strengths and Limitations
Yearly standardized assessments of AF type in a large number
of patients with AF is one of the key strengths of this analysis.
On the other hand, some potential limitations need to be
taken into account in the interpretation of our ﬁndings.
Table 3. Factors Associated With Rhythm Control Interventions
Characteristic (n=2272) Age/Sex Adjusted P Value Multivariable Adjusted P Value
Age 0.86 (0.84–0.89) <0.001 0.88 (0.85–0.92) <0.001
Female sex 1.12 (0.95–1.33) 0.191 1.05 (0.88–1.26) 0.567
BMI 1.01 (1.00–1.03) 0.180 1.01 (1.00–1.03) 0.111
Heart rate 1.03 (1.01–1.05) 0.013 1.02 (1.00–1.05) 0.079
Systolic blood pressure 1.02 (0.99–1.04) 0.120 1.02 (1.00–1.04) 0.118
History of diabetes mellitus 0.95 (0.73–1.23) 0.692 1.02 (0.77–1.34) 0.903
History of coronary artery disease 0.75 (0.60–0.94) 0.014 0.79 (0.62–1.01) 0.058
History of hypertension 1.05 (0.88–1.24) 0.598 1.03 (0.86–1.23) 0.775
History of stroke/TIA 0.85 (0.67–1.09) 0.197 0.91 (0.72–1.17) 0.466
History of heart failure 1.06 (0.84–1.33) 0.650 1.14 (0.89–1.47) 0.285
History of hyperthyroidism 1.24 (0.86–1.78) 0.260 1.08 (0.75–1.57) 0.678
History of renal failure 0.80 (0.60–1.05) 0.109 0.80 (0.59–1.07) 0.129
Regular physical activity 1.32 (1.12–1.56) <0.001 1.42 (1.20–1.68) <0.001
Current smoking 0.98 (0.74–1.28) 0.858 1.04 (0.79–1.37) 0.778
Paroxysmal AF 0.62 (0.52–0.73) <0.001 0.61 (0.51–0.73) <0.001
AF-related symptoms at baseline 1.70 (1.37–2.11) <0.001 1.84 (1.47–2.30) <0.001
Data are hazard ratios (95% CI) based on Cox regression models. Rhythm control intervention was deﬁned as either pulmonary vein isolation, electrical cardioversion, and/or new
amiodarone. Age per 5-year increase; heart rate per 5 beats/min increase, systolic blood pressure per 5 mm Hg increase; multivariable models included all variables from the table (age,
sex, BMI, heart rate, systolic blood pressure, history of diabetes mellitus, history of coronary artery disease, history of hypertension, history of stroke/TIA, history of heart failure, history of
hyperthyroidism, history of renal failure, regular physical activity, current smoking, AF type [paroxysmal AF vs nonparoxysmal AF], AF-related symptoms). A maximum of 60 (2.6%)
observations were deleted because of missing variables. AF indicates atrial ﬁbrillation; BMI, body mass index; TIA, transient ischemic attack.
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Because of the observational study design, we are unable to
prove causality, and residual confounding may persist despite
multivariable adjustment. We did not obtain an ECG recording
during BEAT-AF follow-up visits. However, we collected all
available clinical data (including changes in medication,
available ECGs, and RCIs) to classify the clinical AF type as
accurately as possible. Stratiﬁed analyses showed consistent
results without meaningful differences between the 2 cohorts.
As we did not have continuous ECG monitoring, our analysis
cannot provide an assessment of AF burden but is a reﬂection
of the clinical AF type that is currently used in daily clinical
practice to classify AF patients.
Conclusions
In this large, prospective study of patients with nonpermanent
AF, the incidence of clinical AF progression was relatively low.
A healthy lifestyle may help to prevent a signiﬁcant proportion
of AF progression. The role of RCIs in the prevention of AF
progression is less clear, as patients without RCIs have a
similar progression rate, and determinants for RCIs signiﬁ-
cantly differed from predictors of AF progression.
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Swiss-AF Investigators and Contributors 
 
University Hospital Basel/Basel University: Stefanie Aeschbacher, Steffen Blum, Leo Bonati, 
Lorin Fröhlich, Rebecca Gugganig, Thomas Kofler, Philipp Krisai, Christine Meyer-Zürn, 
Pascal Meyre, Andreas U. Monsch, Christian Müller, Christiane Pudenz, Philipp Reddiess, 
Javier Ruperti Repilado, Aleksandra Schweizer, Anne Springer, Fabienne Steiner, Samuel 
Stempfel, Christian Sticherling, Thomas Szucs, Jan van der Stouwe, Gian Voellmin, Leon 
Zwimpfer. Local Principal Investigator: Michael Kühne; Principal Investigators; Stefan 
Osswald, David Conen 
 
University Hospital Bern: Faculty: Drahomir Aujesky, Urs Fischer, Juerg Fuhrer, Laurent 
Roten, Simon Jung, Heinrich Mattle; Research fellows: Luise Adam, Carole Elodie Aubert, 
Martin Feller, Claudio Schneider, Axel Loewe, Elisavet Moutzouri; Study nurses: Tanja 
Flückiger, Cindy Groen, Nathalie Schwab. Local Principal Investigator: Nicolas Rodondi 
 
Stadtspital Triemli Zurich: Christopher Beynon, Roger Dillier, Franz Eberli, Simone Fontana, 
Christine Franzini, Isabel Juchli, Claudia Liedtke, Jacqueline Nadler, Thayze Obst, Noreen 
Tynan, Xiaoye Schneider, Katrin Studerus, Dominik Weishaupt. Local Principal Investigator: 
Andreas Müller 
 
Kantonspital Baden: Silke Kuest, Karin Scheuch, Denise Hischier, Nicole Bonetti, Corina 
Bello, Henriette Isberg, Alexandra Grau, Jonas Villinger, Mary-Monica Papaux, Eva Laube, 
Philipp Baumgartner, Mark Filipovic, Marcel Frick, Stefanie Leuenberger. Local Principal 
Investigator: Jürg H. Beer 
 
Cardiocentro Lugano: Angelo Auricchio, Adriana Anesini, Cristina Camporini, Giulio Conte, 
Maria Luce Caputo, Francois Regoli, Tiziano Moccetti. Local Principal Investigator: Tiziano 
Moccetti  
 
Kantonsspital St. Gallen: Roman Brenner, David Altmann, Manuela Forrer, Michaela 
Gemperle. Local Principal Investigator: Peter Ammann 
 
Hôpital Cantonal Fribourg: Mathieu Firmann, Sandrine Foucras. Local Principal Investigator: 
Daniel Hayoz 
 
Luzerner Kantonsspital: Benjamin Berte, Andrea Kaeppeli, Myriam Roth, Brigitta Mehmann, 
Markus Pfeiffer, Ian Russi, Kai Schmidt, Vanessa Weberndoerfer, Mabelle Young, Melanie 
Zbinden; Local Principal Investigator: Richard Kobza 
 
Ente Ospedaliero Cantonale Lugano: Luisa Vicari, Jane Frangi-Kultalahti, Tatiana Terrot. 
Local Principal Investigator: Giorgio Moschovitis 
 
University Hospital Geneva: Georg Ehret, Hervé Gallet, Elise Guillermet, Francois Lazeyras, 
Karl-Olof Lovblad, Patrick Perret, Cheryl Teres. Local Principal Investigator: Dipen Shah 
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Table S1 Incidence models. 
Outcome No. of 
events 
py of 
follow-up 
incidence per 
100py 
clinical AF progression 458  8866 5.2 
clinical AF progression from paroxysmal AF 294 6031 4.9 
clinical AF progression from persistent AF 164 2835 5.8 
clinical AF progression among patients without a history of 
ECV or PVI at baseline 
151 2772 5.4 
RCI 617 5663 10.9 
Newly prescribed amiodarone 199 7148 2.8 
ECV 282 6759 4.2 
PVI 358 6327 5.7 
RCI among patients without a history of PVI or ECV 258 3207 8.0 
AF=atrial fibrillation; py=patient years; ECV=electrical cardioversion; PVI=pulmonary vein isolation; 
RCI=rhythm control intervention 
  
D
ow
nloaded from
 http://ahajournals.org by on December 10, 2019
  
Table S2. Risk factors for clinical atrial fibrillation progression in paroxysmal vs. persistent 
atrial fibrillation. 
Characteristic 
 
Paroxysmal 
multivariable adj. 
p-value Persistent 
multivariable adj. 
p-value p-interaction 
Age 1.14 [1.06; 1.22] <0.001 1.31 [1.17; 1.45] <0.001 0.029 
Female Sex 0.84 [0.64; 1.10] 0.207 0.98 [0.68; 1.42] 0.908 0.537 
BMI 1.03 [1.00; 1.05] 0.052 1.03 [0.99; 1.06] 0.181 0.966 
Heart rate 1.07 [1.04; 1.11] <0.001 1.02 [0.98; 1.07] 0.290 0.102 
Systolic blood pressure 1.02 [0.99; 1.05] 0.233 1.04 [1.00; 1.09] 0.065 0.475 
History of diabetes 0.84 [0.58; 1.21] 0.341 1.11 [0.71; 1.72] 0.650 0.329 
History of coronary artery disease 0.99 [0.73; 1.32] 0.918 0.98 [0.66; 1.45] 0.913 0.968 
History of hypertension 0.91 [0.69; 1.21] 0.255 1.09 [0.74; 1.62] 0.667 0.468 
History of stroke and/or TIA 1.46 [1.09; 1.94] 0.010 1.54 [1.05; 2.27] 0.027 0.778 
History of heart failure 2.07 [1.53; 2.80] <0.001 1.24 [0.86; 1.78] 0.251 0.033 
History of hyperthyroidism 1.92 [1.11; 3.31] 0.020 1.49 [0.85; 2.61] 0.162 0.556 
History of renal failure 1.17 [0.83; 1.63] 0.375 1.03 [0.68; 1.58] 0.885 0.662 
Regular physical activity 0.81 [0.63; 1.03] 0.084 0.80 [0.58; 1.12] 0.189 0.986 
Current smoking 1.07 [0.69; 1.66] 0.775 0.97 [0.52; 1.84] 0.936 0.804 
History of pulmonary vein 
isolation 
0.87 [0.64; 1.20] 0.405 0.44 [0.26; 0.73] 0.002 0.026 
AF related symptoms at baseline 0.95 [0.71; 1.25] 0.693 0.78 [0.55; 1.09] 0.148 0.390 
Amiodarone use at baseline 0.99 [0.73; 1.36] 0.970 0.76 [0.51; 1.13] 0.169 0.289 
Data are hazard ratios (HR) (95% confidence intervals [CI]) based on Cox regression models. Age per 5 
years increase; Heart Rate per 5 beats/min increase, Systolic blood pressure per 5mmHg increase; Models 
included all variables from the table (age, sex, BMI, heart rate, systolic blood pressure, history of diabetes, 
history of coronary artery disease, history of hypertension, history of stroke/TIA, history of heart failure, 
history of hyperthyroidism, history of renal failure, regular physical activity, current smoking, history of 
pulmonary vein isolation, AF related symptoms, amiodarone).  
A maximum of 85 (3.0%) observations were deleted due to missing variables.  
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Table S3. Risk factors for clinical atrial fibrillation progression in BEAT-AF vs. Swiss-AF. 
Characteristic 
 
BEAT-AF 
multivariable adj. 
p-value Swiss-AF 
multivariable adj. 
p-value 
Age 1.22 [1.12; 1.33] <0.001 1.09 [1.00; 1.18] 0.063 
Female Sex 0.83 [0.59; 1.16] 0.270 0.87 [0.66; 1.16] 0.355 
BMI 1.02 [0.99; 1.06] 0.216 1.01 [0.98; 1.04] 0.458 
Heart rate 1.01 [0.97; 1.05] 0.619 1.12 [1.08; 1.16] <0.001 
Systolic blood pressure 1.04 [1.00; 1.09] 0.069 1.01 [0.98; 1.05] 0.421 
History of diabetes 0.80 [0.48; 1.33] 0.382 0.83 [0.59; 1.17] 0.282 
History of coronary artery disease 1.06 [0.71; 1.58] 0.763 0.92 [0.69; 1.23] 0.558 
History of hypertension 0.87 [0.61; 1.23] 0.414 1.10 [0.81; 1.49] 0.536 
History of stroke and/or TIA 1.12 [0.72; 1.72] 0.620 1.42 [1.08; 1.88] 0.012 
History of heart failure 2.28 [1.56; 3.34] <0.001 1.37 [1.03; 1.82] 0.032 
History of hyperthyroidism 2.72 [1.61; 4.60] <0.001 1.08 [0.59; 2.00] 0.800 
History of renal failure 0.66 [0.40; 1.10] 0.112 1.31 [0.97; 1.78] 0.081 
Regular physical activity 0.74 [0.54; 1.00] 0.051 0.87 [0.67; 1.12] 0.263 
Current smoking 1.00 [0.56; 1.80] 0.999 1.03 [0.65; 1.64] 0.902 
Paroxysmal AF at baseline 0.86 [0.61; 1.20] 0.367 1.27 [0.97; 1.65] 0.077 
History of pulmonary vein 
isolation 
0.86 [0.59; 1.25] 0.432 0.45 [0.31; 0.68] <0.001 
AF related symptoms at baseline 1.12 [0.76; 1.65] 0.565 0.78 [0.60; 1.02] 0.068 
Amiodarone use at baseline 0.92 [0.63; 1.35] 0.669 0.94 [0.69; 1.30] 0.713 
Data are hazard ratios (HR) (95% confidence intervals [CI]) based on Cox regression models. Age per 5 
years increase; Heart Rate per 5 beats/min increase, Systolic blood pressure per 5mmHg increase; Models 
included all variables from the table (age, sex, BMI, heart rate, systolic blood pressure, history of diabetes, 
history of coronary artery disease, history of hypertension, history of stroke/TIA, history of heart failure, 
history of hyperthyroidism, history of renal failure, regular physical activity, current smoking, AF type, 
history of pulmonary vein isolation, AF related symptoms, amiodarone). A maximum of 33 (2.8%) 
[BEAT-AF] and 52 (3.1%) [Swiss-AF] observations were deleted due to missing variables.  
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Table S4. Baseline characteristics stratified by rhythm control intervention. 
 
Characteristic No intervention 
n=1655 
PVI 
n=221 
ECV 
n=107 
Amiodarone 
n=101 
>1 intervention 
n=188 
p-value 
       
Age [years ] 71 ± 10 62 ± 10 68 ± 10 73 ± 6 66 ± 9 <0.001 
Female sex, No. (%) 491 (29.7) 71 (32.1) 32 (29.9) 35 (34.7) 56 (29.8) 0.812 
Body mass index [kg/m2] 26.9 ± 4.6 26.4 ± 3.9 27.6 ± 4.3 27.6 ± 4.6 27.8 ± 4.3 <0.001 
Heart rate [beats/min] 65 [58; 75] 63 [54; 72] 68 [60; 82] 66 [57; 73] 68 [58; 79] 0.006 
Systolic blood pressure [mmHg] 134 ± 18 134 ± 18 134 ± 20 136 ± 19 135 ± 20 0.025 
History of coronary heart disease, No. (%) 409 (24.7) 20 (9.1) 23 (21.5) 28 (27.7) 21 (11.2) <0.001 
History of stroke/TIA, No. (%) 375 (17.9) 23 (8.4) 30 (17.8) 20 (19.8) 23 (10.1) <0.001 
History of hypertension, No. (%) 1096 (66.2) 105 (47.5) 72 (67.3) 80 (79.2) 121 (64.4) <0.001 
History of heart failure, No. (%) 279 (16.9) 12 (5.4) 24 (22.4) 21 (20.8) 29 (15.4) <0.001 
History of diabetes mellitus, No. (%) 224 (13.5) 15 (6.8) 20 (18.7) 13 (12.9) 17 (9.0) 0.008 
History of renal failure, No. (%) 264 (16.0) 5 (2.3) 19 (17.8) 19 (18.8) 14 (7.5) <0.001 
History of hyperthyroidism, No. (%) 66 (4.0) 11 (5.0) 7 (6.5) 3 (3.0) 9 (4.8) 0.646 
Current Smoker, No. (%) 129 (7.8) 27 (12.2) 10 (9.4) 11 (11.1) 12 (6.4) 0.133 
Regular physical activity, No. (%) 834 (50.5) 144 (65.5) 64 (59.8) 56 (56.6) 108 (57.5) <0.001 
AF related symptoms, No. (%) 1105 (68.1) 207 (93.7) 79 (73.8) 73 (73.7) 153 (81.4) <0.001 
 
TIA=transient ischaemic attack; p-values were based on Chi-squared or Kruskal Wallis tests as appropriate 
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Table S5. Factors associated with rhythm control interventions among patients without a history 
of pulmonary vein isolation and/or electrical cardioversion. 
Characteristic 
n=1221 
 
HR (95% CI) 
age/sex adj. 
p-value HR (95% CI) 
multivariable 
adj. 
p-value 
Age 0.83 [0.79; 0.87] <0.001 0.86 [0.81; 0.91] <0.001 
Female Sex 1.11 (0.86; 1.43) 0.440 0.99 [0.76; 1.30] 0.953 
BMI 1.00 [0.98; 1.03] 0.975 1.01 [0.98; 1.04] 0.474 
Heart Rate 1.04 [1.01; 1.08] 0.014 1.05 [1.02; 1.09] 0.005 
Systolic blood pressure 1.03 [1.00; 1.07] 0.073 1.04 [1.00; 1.08] 0.038 
History of diabetes 0.78 [0.53; 1.17] 0.235 0.84 [0.55; 1.28] 0.412 
History of coronary artery disease 0.62 [0.44; 0.89] 0.008 0.69 [0.48; 0.99] 0.044 
History of hypertension 1.05 [0.80; 1.39] 0.705 1.06 [0.80; 1.42] 0.682 
History of heart failure 0.94 [0.64; 1.38] 0.752 1.21 [0.81; 1.81] 0.361 
History of stroke/TIA 0.76 [0.54; 1.07] 0.1118 0.76 [0.53; 1.08] 0.125 
History of hyperthyroidism 1.21 [0.57; 2.57] 0.618 1.27 [0.59; 2.70] 0.542 
History of renal failure 0.82 [0.54; 1.24] 0.352 0.90 [0.58; 1.39] 0.629 
Regular physical activity 1.58 [1.23; 2.03] <0.001 1.68 [1.29; 2.18] <0.001 
Current smoking 0.93 [0.60; 1.44] 0.744 1.06 [0.68; 1.65] 0.815 
Paroxysmal AF 0.81 [0.58; 1.13] 0.218 0.80 [0.57; 1.13] 0.208 
AF related symptoms at baseline 1.81 [1.28; 2.57] <0.001 1.78 [1.25; 2.54] 0.001 
 
Data are hazard ratios (HR) (95% confidence intervals [CI]) based on Cox regression models. 
Rhythm control intervention was defined as either pulmonary vein isolation, electrical cardioversion and/or new 
amiodarone. 
Age per 5 years increase; Heart Rate per 5 beats/min increase, Systolic blood pressure per 5mmHg increase; 
Multivariable models included all variables from the table (age, sex, BMI, heart rate, systolic blood pressure, 
history of diabetes, history of coronary artery disease, history of hypertension, history of heart failure, history of 
stroke /TIA, history of hyperthyroidism, history of renal failure, regular physical activity, current smoking, 
paroxysmal AF, AF related symptoms). 
A maximum of 32 (2.6%) observations were deleted due to missing predictor variables 
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